HTBX Heat Biologics Inc.

1.14
0  0%
Previous Close 1.14
Open 1.15
Price To Book 1.28
Market Cap 38841308
Shares 34,071,323
Volume 163,931
Short Ratio
Av. Daily Volume 625,197

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 additional data due 4Q 2019.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)

Latest News

  1. Heat Biologics CEO to Present at the ThinkEquity Conference in New York City
  2. HTBX: 2018 Financial & Operational Results
  3. Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019
  4. Heat Biologics Reports 2018 Results and Provides Corporate Update
  5. Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
  6. HTBX: HS-110 Interim Update
  7. Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai
  8. Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
  9. These Four Healthcare Stocks Are Heating Up On Tuesday
  10. What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?
  11. UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
  12. Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
  13. The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
  14. Heat Biologics Provides Clinical and Business Update
  15. Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
  16. Heat Biologics to Present at Biotech Showcase 2019 in California
  17. HTBX: Plenty of Catalysts in 2019
  18. Durham company rakes in another $13.8M through public offering
  19. Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering
  20. Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum